2. Academic Validation
  3. Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling

Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling

  • Nat Commun. 2021 Mar 19;12(1):1747. doi: 10.1038/s41467-021-21549-x.
Chen Yang  # 1 2 3,  Chengzhe Tian  # 1 2,  Timothy E Hoffman  # 1 2,  Nicole K Jacobsen 1 2,  Sabrina L Spencer 4 5
Affiliations

Affiliations

  • 1 Department of Biochemistry, University of Colorado Boulder, Boulder, CO, USA.
  • 2 BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA.
  • 3 Department of Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, CO, USA.
  • 4 Department of Biochemistry, University of Colorado Boulder, Boulder, CO, USA. sabrina.spencer@colorado.edu.
  • 5 BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA. sabrina.spencer@colorado.edu.
  • # Contributed equally.
PMID: 33741929 DOI: 10.1038/s41467-021-21549-x
Abstract

Despite the increasing number of effective anti-cancer therapies, successful treatment is limited by the development of drug resistance. While the contribution of genetic factors to drug resistance is undeniable, little is known about how drug-sensitive cells first evade drug action to proliferate in drug. Here we track the responses of thousands of single melanoma cells to BRaf inhibitors and show that a subset of cells escapes drug via non-genetic mechanisms within the first three days of treatment. Cells that escape drug rely on ATF4 stress signalling to cycle periodically in drug, experience DNA replication defects leading to DNA damage, and yet out-proliferate Other cells over extended treatment. Together, our work reveals just how rapidly melanoma cells can adapt to drug treatment, generating a mutagenesis-prone subpopulation that expands over time.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18972
    99.94%, BRAF Inhibitor
    Raf